IP Library Granted Patent US 7,973,065
Granted Patent B2
US 7,973,065 · App. 12/898,806 · Granted Jul 5, 2011

Antimicrobial compounds

Assignee: Shaw Intellectual Properties Holding, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,973,065
App. No.
12/898,806
Granted
Jul 5, 2011
Kind
B2
Abstract

The compounds disclosed herein are isoxazole derivatives that are useful as antimicrobial compounds, particularly as anti-bacterial compounds. The disclosed methods comprise incubating at least two different substrates in the presence of at least one oxygenase to provide the disclosed compounds, or to prepare and identify compounds that have antimicrobial activity.

Claims (66)

1. A compound of the formula:

wherein:

X 1 -X 3 are independently selected from N, NH, O, S, CH, and CH 2 ;

R 1 is selected from hydrogen, hydroxy, and C 1 -C 4 alkyl;

R 2a -R 2d are independently selected from hydrogen, hydroxy, halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, cyano, and nitro; and

each ------ is independently an optional bond; or

a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , of the formula:

3. The compound of claim 1 , of the formula:

4. The compound of claim 1 , wherein R 1 is hydrogen.

5. The compound of claim 1 , wherein R 2a -R 2d are independently selected from hydrogen, hydroxy, and halogen.

6. The compound of claim 1 , selected from:

4-(3-oxoindolin-2-ylidene)benzo[c]isoxazol-5(4H)-one;

4-(4-fluoro-3-oxoindolin-2-ylidene)benzo[c]isoxazol-5(4H)-one;

4-(4-chloro-3-oxoindolin-2-ylidene)benzo[c]isoxazol-5(4H)-one;

4-(5-fluoro-3-oxoindolin-2-ylidene)benzo[c]isoxazol-5(4H)-one;

4-(5-chloro-3-oxoindolin-2-ylidene)benzo[c]isoxazol-5(4H)-one;

4-(6-fluoro-3-oxoindolin-2-ylidene)benzo[c]isoxazol-5(4H)-one;

4-(6-chloro-3-oxoindolin-2-ylidene)benzo[c]isoxazol-5(4H)-one;

4-(7-fluoro-3-oxoindolin-2-ylidene)benzo[c]isoxazol-5(4H)-one; and

4-(7-chloro-3-oxoindolin-2-ylidene)benzo[c]isoxazol-5(4H)-one.

7. The compound of claim 1 , selected from:

7-(3-oxoindolin-2-ylidene)-7,7a-dihydrobenzo[d]isoxazol-6(3aH)-one;

7-(4-fluoro-3-oxoindolin-2-ylidene)-7,7a-dihydrobenzo[d]isoxazol-6(3aH)-one;

7-(4-chloro-3-oxoindolin-2-ylidene)-7,7a-dihydrobenzo[d]isoxazol-6(3aH)-one;

7-(5-fluoro-3-oxoindolin-2-ylidene)-7,7a-dihydrobenzo[d]isoxazol-6(3aH)-one;

7-(5-chloro-3-oxoindolin-2-ylidene)-7,7a-dihydrobenzo[d]isoxazol-6(3aH)-one;

7-(6-fluoro-3-oxoindolin-2-ylidene)-7,7a-dihydrobenzo[d]isoxazol-6(3aH)-one;

7-(6-chloro-3-oxoindolin-2-ylidene)-7,7a-dihydrobenzo[d]isoxazol-6(3aH)-one;

7-(7-fluoro-3-oxoindolin-2-ylidene)-7,7a-dihydrobenzo[d]isoxazol-6(3aH)-one; and

7-(7-chloro-3-oxoindolin-2-ylidene)-7,7a-dihydrobenzo[d]isoxazol-6(3aH)-one.

8. A method of treating a bacterial infection in a subject in need thereof, comprising:

administering to the subject a therapeutically effective amount of a compound of the formula:

wherein:

X 1 -X 3 are independently selected from N, NH, O, S, CH, and CH 2 ;

R 1 is selected from hydrogen, hydroxy, and C 1 -C 4 alkyl;

R 2a -R 2d are independently selected from hydrogen, hydroxy, halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, cyano, and nitro; and

each ------ is independently an optional bond; or

a pharmaceutically acceptable salt thereof.

9. The method of claim 8 , wherein the compound is of the formula:

10. The method of claim 8 , wherein the compound is of the formula:

11. The method of claim 8 , wherein R 1 is hydrogen.

12. The method of claim 8 , wherein R 2a -R 2d are independently selected from hydrogen, hydroxy, and halogen.

13. The method of claim 8 , wherein the compound is selected from:

4-(3-oxoindolin-2-ylidene)benzo[c]isoxazol-5(4H)-one;

4-(4-fluoro-3-oxoindolin-2-ylidene)benzo[c]isoxazol-5(4H)-one;

4-(4-chloro-3-oxoindolin-2-ylidene)benzo[c]isoxazol-5(4H)-one;

4-(5-fluoro-3-oxoindolin-2-ylidene)benzo[c]isoxazol-5(4H)-one;

4-(5-chloro-3-oxoindolin-2-ylidene)benzo[c]isoxazol-5(4H)-one;

4-(6-fluoro-3-oxoindolin-2-ylidene)benzo[c]isoxazol-5(4H)-one;

4-(6-chloro-3-oxoindolin-2-ylidene)benzo[c]isoxazol-5(4H)-one;

4-(7-fluoro-3-oxoindolin-2-ylidene)benzo[c]isoxazol-5(4H)-one; and

4-(7-chloro-3-oxoindolin-2-ylidene)benzo[c]isoxazol-5(4H)-one.

14. The method of claim 8 , wherein the compound is selected from:

7-(3-oxoindolin-2-ylidene)-7,7a-dihydrobenzo[d]isoxazol-6(3aH)-one;

7-(4-fluoro-3-oxoindolin-2-ylidene)-7,7a-dihydrobenzo[d]isoxazol-6(3aH)-one;

7-(4-chloro-3-oxoindolin-2-ylidene)-7,7a-dihydrobenzo[d]isoxazol-6(3aH)-one;

7-(5-fluoro-3-oxoindolin-2-ylidene)-7,7a-dihydrobenzo[d]isoxazol-6(3aH)-one;

7-(5-chloro-3-oxoindolin-2-ylidene)-7,7a-dihydrobenzo[d]isoxazol-6(3aH)-one;

7-(6-fluoro-3-oxoindolin-2-ylidene)-7,7a-dihydrobenzo[d]isoxazol-6(3aH)-one;

7-(6-chloro-3-oxoindolin-2-ylidene)-7,7a-dihydrobenzo[d]isoxazol-6(3aH)-one;

7-(7-fluoro-3-oxoindolin-2-ylidene)-7,7a-dihydrobenzo[d]isoxazol-6(3aH)-one; and

7-(7-chloro-3-oxoindolin-2-ylidene)-7,7a-dihydrobenzo[d]isoxazol-6(3aH)-one.

15. The method of claim 8 , wherein the subject has a M. smegmatis or B. subtilis infection.

16. The method of claim 8 , wherein the subject has an M. tuberculosis infection.

17. The method of claim 8 , wherein the subject has a drug resistant or extensively drug resistant M. tuberculosis infection.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded May 28, 2024
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
To: APTIM INTELLECTUAL PROPERTY HOLDINGS, LLC (FKA SHAW INTELLECTUAL PROPERTY HOLDINGS, LLC); APTIM GOVERNMENT SOLUTIONS, LLC (FKA CB&I GOVERNMENT SOLUTIONS, LLC)
Reel/Frame 067535/0309 →
SECURITY INTEREST Recorded May 24, 2024
From: APTIM GOVERNMENT SOLUTIONS, LLC; APTIM INTELLECTUAL PROPERTY HOLDINGS, LLC
To: JPMORGAN CHASE BANK, N.A., AS JUNIOR LIEN COLLATERAL AGENT
Reel/Frame 067524/0085 →
SECURITY INTEREST Recorded May 23, 2024
From: APTIM GOVERNMENT SOLUTIONS, LLC; APTIM INTELLECTUAL PROPERTY HOLDINGS, LLC
To: JPMORGAN CHASE BANK, N.A., AS SENIOR SECURED COLLATERAL AGENT
Reel/Frame 067514/0322 →
CHANGE OF NAME Recorded Mar 2, 2018
From: SHAW INTELLECTUAL PROPERTY HOLDINGS, LLC
To: APTIM INTELLECTUAL PROPERTY HOLDINGS, LLC
Reel/Frame 045513/0376 →
SECURITY INTEREST Recorded Jul 6, 2017
From: SHAW INTELLECTUAL PROPERTY HOLDINGS, LLC; CB&I GOVERNMENT SOLUTIONS, LLC; LFG SPECIALTIES, L.L.C.; CB&I ENVIRONMENTAL & INFRASTRUCTURE, INC.
To: U.S. BANK NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT
Reel/Frame 042915/0657 →
SECURITY INTEREST Recorded Jun 30, 2017
From: SHAW INTELLECTUAL PROPERTY HOLDINGS, LLC; CB&I GOVERNMENT SOLUTIONS, LLC; LFG SPECIALTIES, L.L.C.; CB&I ENVIRONMENTAL & INFRASTRUCTURE, INC.
To: UBS AG, STAMFORD BRANCH, AS ABL COLLATERAL AGENT
Reel/Frame 042875/0116 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2010
From: MCCLAY, KEVIN ROCK; STEFFAN, ROBERT JON
To: SHAW INTELLECTUAL PROPERTIES HOLDING, INC.
Reel/Frame 025141/0190 →
Continuity (2)
Provisional Application 61249396 · Oct 7, 2009
Related Publication 20110082180A1 · Apr 7, 2011